…A phase III trial of dalfampridine, or 4-aminopyridine in an oral extended-release formulation, has found that the agent appears to improve walking ability in MS patients (Goodman et al. Ann Neurol 2010; 68: 494-502). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…White matter hyperintensities are a predictor of cognitive decline in relatively healthy older subjects, according to data from the Alzheimer Disease Neuroimaging Initiative (Carmichael et al. Arch Neurol 2010; 67: 1370-1378). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…ic Working Group has recommended the Montreal Cognitive Assessment (MoCA) as the most suitable tool to detect mild cognitive impairment (MCI) in patients with Parkinson’s disease (Chou et al. Mov Disord 2010; 25: 2501-2507). The task force further recommended that the MoCA be employed in clinical trials of PD where the primary outcome is not cognitive performance. Subscribe to read more It takes 30 seconds or login using your email address Please…
…While a number of studies have suggested that Parkinson’s disease and melanoma frequently co-occur, a new study has reported that no genetic link could be found between the diseases. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…models to alter beta-amyloid accumulation and to have anti-apoptotic activity (Oksman et al. Neurobiol Dis 2006; 23: 563-572). For a recent review see Jicha & Markesbery. Clin Interv Aging 2010; 5: 45-61; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC2854051/pdf/cia-5-045.pdf. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…